Comparison of new different assay systems for thyrotropin receptor antibodies with reference to thyroid-stimulating antibodies and thyroid stimulation-blocking antibodies in Graves' disease.

International journal of clinical pharmacology research Pub Date : 2004-01-01

Y Hirooka, C Li, J Takagi, M Gotoh, S Habu, T Yasaka-Nomura, R Ishihara, Y Nakasone, R Nakamura, R Morikawa, K Otake, T Nogimori, Y Ishizuki

{"title":"Comparison of new different assay systems for thyrotropin receptor antibodies with reference to thyroid-stimulating antibodies and thyroid stimulation-blocking antibodies in Graves' disease.","authors":"Y Hirooka, C Li, J Takagi, M Gotoh, S Habu, T Yasaka-Nomura, R Ishihara, Y Nakasone, R Nakamura, R Morikawa, K Otake, T Nogimori, Y Ishizuki","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>The aim of our study was to evaluate the diagnostic sensitivity of the new thyrotropin receptor antibody (TRAb) assays (Cosmic TRAb CT, ELISA and Yamasa DYNOtest TRAb). TRAb was positive in 43 of 44 (97.7%) untreated patients with Graves' disease by both TRAb CT and/or ELISA and NYNOtest TRAb. Thus the new TRAb assays were clearly more sensitive than the conventional assay (positivity: 85%). There was a strong positive correlation between the data obtained in TRAb CT and/or ELISA and those obtained in DYNOtest TRAb (r = 0.942, p < 0.0001). There was a significant correlation between the new TRAb and TSAb (r = 0.696, p < 0.0001). Although there was a significant correlation between the new TRAb and thyroid stimulation-blocking antibody (TSBAb), the correlation coefficient was low (r = 0.605, p < 0.0001). The increased sensitivity of the new TRAb assays for Graves' disease provides an advantage over conventional assay.</p>","PeriodicalId":13940,"journal":{"name":"International journal of clinical pharmacology research","volume":"24 4","pages":"111-6"},"PeriodicalIF":0.0000,"publicationDate":"2004-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International journal of clinical pharmacology research","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

The aim of our study was to evaluate the diagnostic sensitivity of the new thyrotropin receptor antibody (TRAb) assays (Cosmic TRAb CT, ELISA and Yamasa DYNOtest TRAb). TRAb was positive in 43 of 44 (97.7%) untreated patients with Graves' disease by both TRAb CT and/or ELISA and NYNOtest TRAb. Thus the new TRAb assays were clearly more sensitive than the conventional assay (positivity: 85%). There was a strong positive correlation between the data obtained in TRAb CT and/or ELISA and those obtained in DYNOtest TRAb (r = 0.942, p < 0.0001). There was a significant correlation between the new TRAb and TSAb (r = 0.696, p < 0.0001). Although there was a significant correlation between the new TRAb and thyroid stimulation-blocking antibody (TSBAb), the correlation coefficient was low (r = 0.605, p < 0.0001). The increased sensitivity of the new TRAb assays for Graves' disease provides an advantage over conventional assay.

本刊更多论文

Graves病促甲状腺激素受体抗体及促甲状腺阻断抗体新检测系统的比较。

本研究的目的是评估新的促甲状腺激素受体抗体(TRAb)检测方法(Cosmic TRAb CT、ELISA和Yamasa DYNOtest TRAb)的诊断敏感性。经TRAb CT和/或ELISA及NYNOtest TRAb检测，44例未经治疗的Graves病患者中有43例(97.7%)TRAb呈阳性。因此，新的TRAb测定法明显比传统的测定法更敏感(阳性率:85%)。TRAb CT和/或ELISA所得数据与DYNOtest TRAb所得数据呈正相关(r = 0.942, p < 0.0001)。新TRAb与TSAb有显著相关性(r = 0.696, p < 0.0001)。虽然新TRAb与甲状腺刺激阻断抗体(TSBAb)有显著相关，但相关系数较低(r = 0.605, p < 0.0001)。新的TRAb检测格雷夫斯病的灵敏度增加，比传统的检测方法有优势。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

International journal of clinical pharmacology research

自引率

0.00%

发文量